[Form 4] PhenixFIN Corporation 5.25% Notes due 2028 Insider Trading Activity
Lowell W. Robinson, a director of PhenixFIN Corporation (ticker PFX), purchased shares of the issuer’s common stock on two consecutive days. On 08/19/2025 he acquired 189 shares at a weighted average price of $49.25 per share, increasing his beneficial ownership to 2,100 shares. On 08/20/2025 he acquired an additional 75 shares at $49.28 per share, bringing his total to 2,175 shares. The Form 4 notes the 08/19 price is a weighted average for multiple trades that ranged from $49.10 to $49.27, and the reporting person offers to provide detailed fill-level prices on request.
- Director purchase disclosed: Lowell W. Robinson purchased 189 and 75 shares on 08/19/2025 and 08/20/2025, respectively.
- Transparent pricing disclosure: Form 4 includes a weighted-average price and a noted price range ($49.10–$49.27) with offer to provide trade-level details.
- Post-transaction holdings reported: Beneficial ownership updated to 2,100 shares after 08/19/2025 and 2,175 shares after 08/20/2025.
- None.
Insights
TL;DR: Insider purchases of 264 shares across two days at about $49.26 each, modest in absolute size but aligns management with equity.
The reporting shows routine open-market purchases by a director, totaling 264 shares acquired on 08/19/2025 and 08/20/2025 at weighted prices of $49.25 and $49.28. The filings disclose the post-transaction beneficial holdings of 2,100 and 2,175 shares. These transactions are documented with the required weighted-average disclosure and an offer to provide trade-level detail, indicating compliance with Section 16 reporting. Without additional context on outstanding shares or insider holdings, the transactions appear to be small, documented insider buys rather than transformative corporate events.
TL;DR: Form 4 shows standard director purchases and proper disclosure; no governance concerns evident from the form itself.
The Form 4 identifies Lowell W. Robinson as a director and lists two non-derivative open-market purchases with clear reporting of amounts and weighted pricing, including a footnote disclosing the price range for the aggregated trade. The signature and explanatory footnote meet disclosure norms. The document does not report any derivative transactions, sales, plan-based trades, or changes in reporting status, so there are no governance red flags apparent from this filing alone.